Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.

Molecular portraits of human breast tumours

2000 • 15,445 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

2001 • 10,602 citations

Gene expression profiling predicts clinical outcome of breast cancer

2002 • 9,314 citations

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

2002 • 6,428 citations

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

2001 • 6,216 citations

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

2004 • 5,895 citations

Repeated observation of breast tumor subtypes in independent gene expression data sets

2003 • 5,356 citations

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1998 • 4,104 citations

Tamoxifen for early breast cancer: an overview of the randomised trials

1998 • 4,082 citations

Cancer Metastasis: Building a Framework

2006 • 4,071 citations

Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

2006 • 3,623 citations

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 • 3,283 citations

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

2004 • 2,644 citations

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

2006 • 2,484 citations

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

2005 • 2,221 citations

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

1998 • 2,199 citations

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

2004 • 1,746 citations

A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors

1989 • 1,471 citations

Concordance among Gene-Expression–Based Predictors for Breast Cancer

2006 • 1,336 citations

Predicting the clinical status of human breast cancer by using gene expression profiles

2001 • 1,336 citations

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

2006 • 1,213 citations

The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration

2003 • 1,176 citations

Fundamentals of experimental design for cDNA microarrays

2002 • 1,070 citations

Automated subcellular localization and quantification of protein expression in tissue microarrays

2002 • 764 citations

Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer

2005 • 617 citations

Infrared spectroscopic imaging for histopathologic recognition

2005 • 560 citations

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

2004 • 545 citations

Navigating gene expression using microarrays — a technology review

2001 • 537 citations

Converting a breast cancer microarray signature into a high-throughput diagnostic test

2006 • 489 citations

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

2003 • 464 citations

Microarray Analysis and Tumor Classification

2006 • 451 citations

Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

2001 • 425 citations

Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling

2005 • 331 citations

TAILORx: Trial Assigning Individualized Options for Treatment (Rx)

2006 • 259 citations

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

2003 • 231 citations

Between-group analysis of microarray data

2002 • 225 citations

Cancer biomarkers: a systems approach

2006 • 197 citations

Association Between Pak1 Expression and Subcellular Localization and Tamoxifen Resistance in Breast Cancer Patients

2006 • 197 citations

Microarray platforms – comparisons and contrasts

2004 • 196 citations

Biomarker discovery and validation: technologies and integrative approaches

2004 • 185 citations

Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

2003 • 176 citations

Predictive Markers in Breast and Other Cancers: A Review

2005 • 176 citations

The US Food and Drug Administration perspective on cancer biomarker development

2006 • 171 citations

The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro

2003 • 169 citations

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

2004 • 160 citations

Embracing the complexity of genomic data for personalized medicine

2006 • 148 citations

CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance

2006 • 135 citations

Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification

2005 • 129 citations

The Presence of a Fibrotic Focus in Invasive Breast Carcinoma Correlates with the Expression of Carbonic Anhydrase IX and is a Marker of Hypoxia and Poor Prognosis

2003 • 129 citations

Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

2006 • 125 citations

Diagnostics and biomarker development: priming the pipeline

2006 • 118 citations

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up

2004 • 117 citations

CENP‐F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer

2007 • 114 citations

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

2004 • 111 citations

The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase

2005 • 105 citations

Clinical trial design for microarray predictive marker discovery and assessment

2004 • 98 citations

Optimization of Recovery of RNA From Formalin-fixed, Paraffin-embedded Tissue

2006 • 94 citations

Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer

2005 • 87 citations

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

2006 • 82 citations

Hypoxia inducible factor‐1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response

2005 • 79 citations

Tissue microarrays: bridging the gap between research and the clinic

2005 • 68 citations

Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response

2005 • 59 citations

Molecular biology of breast cancer

2006 • 54 citations

The promise of metabolomics in cancer molecular therapeutics.

2004 • 53 citations

Real-time Quantitative RT-PCR Shows Variable, Assay-dependent Sensitivity to Formalin Fixation: Implications for Direct Comparison of Transcript Levels in Paraffin-embedded Tissues

2006 • 51 citations

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

2005 • 48 citations

The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response

2006 • 44 citations

[1] RNA Extraction for Arrays

2006 • 42 citations

Molecular profiling of breast cancer

2006 • 40 citations

Transfer and multiplex immunoblotting of a paraffin embedded tissue

2006 • 40 citations

[20] The Application of Tissue Microarrays in the Validation of Microarray Results

2006 • 39 citations

Breast Cancer–Amplified Sequence 3, a Target of Metastasis-Associated Protein 1, Contributes to Tamoxifen Resistance in Premenopausal Patients with Breast Cancer

2006 • 35 citations

Microarray Technologies 2003 - An Overview

2003 • 20 citations

New data on chemotherapy in the adjuvant setting

2003 • 19 citations

The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line

2006 • 17 citations

Mammary gland biology and breast cancer

2006 • 16 citations

Breast cancer proteomics: clinical perspectives

2007 • 9 citations

Functional interrogation of breast cancer: from models to drugs

2006 • 4 citations